Connect with us

Technology

NewView Capital and Carta Announce Strategic Collaboration to Support Company-Sponsored Tender Offers

Published

on

The collaboration combines NewView Capital’s venture expertise and direct secondaries experience with Carta’s leading private capital platform to help companies seamlessly deliver liquidity to investors and employees through company-sponsored tender offers.

SAN FRANCISCO, Sept. 22, 2026 /PRNewswire/ — NewView Capital (“NewView”), a venture growth firm specializing in secondary and primary capital investments, and Carta, the connected platform and AI-native ecosystem for private capital, today announced a collaboration to facilitate company-sponsored tender offers. The relationship combines NewView’s expertise in venture and direct secondaries with Carta’s integrated equity management and liquidity platform, giving founders a more streamlined way to plan and execute company-sponsored liquidity programs.

Private markets have changed significantly over the past decade as venture-backed companies remain private longer and exit timelines continue to extend. Tender offers are becoming a strategic tool for companies to recruit and retain employees, provide liquidity to early shareholders, maintain healthy cap tables, and continue scaling as private businesses.

Industry data shows that a growing number of companies are launching tender offers and with greater frequency, reflecting a broader shift toward structured liquidity as a routine part of private company operations. As demand grows, founders need infrastructure that facilitates execution without adding operational burden, so they can remain focused on company building. 

In the first half of 2026, Carta administered 70+ tender offers representing $3B in transaction volume, the strongest H1 on record. Carta’s end-to-end transaction infrastructure will complement NewView’s experience structuring and investing in company-sponsored tender offers. Together, NewView and Carta will help companies navigate the tender process from planning through close via a single coordinated workflow, reducing the complexity that often accompanies liquidity events. Several company-sponsored tender offers are already underway through the collaboration, with additional programs expected in the coming months.

Founded in 2018 through a landmark $1.35 billion secondary transaction, NewView Capital was built on the belief that venture secondaries would become a foundational part of the innovation economy. Since inception, the firm has completed more than 500 secondary transactions, helping founders, employees, and investors realize liquidity while supporting companies’ long-term growth. The relationship with Carta extends NewView’s commitment to bringing greater insight and efficiency to the venture secondary market.

“Carta is where many of the world’s leading private companies already manage ownership, making it a natural partner for NewView,” said Ravi Viswanathan, Founder and Managing Partner of NewView Capital. “Companies are choosing to stay private far longer, making liquidity an essential part of the private company lifecycle. Employees, founders, and early investors shouldn’t have to wait a decade or more for an opportunity to realize value. By bringing together Carta’s platform and NewView’s secondary expertise, we’re making it easier for founders to run thoughtful, well-executed liquidity programs.”

“NewView brings real depth within venture capital secondaries. They’ve completed hundreds of transactions and understand where the complexity lies,” said Rohin Shah, Head of Strategic Partnerships at Carta. “At Carta, we are seeing firsthand that tender offers have shifted from a one-time event to a regular and recurring way for private companies to manage their cap tables, and retain and incentivize talent. This collaboration gives founders both the right infrastructure and the right capital partner to seamlessly offer liquidity to their employees and investors.”

The partnership reflects the growing need for purpose-built infrastructure as private markets mature. Founders need liquidity solutions that combine trusted technology, streamlined transaction workflows, and experienced secondary capital partners. Together, NewView Capital and Carta aim to make structured liquidity more accessible and scalable for the next generation of private companies.

About NewView Capital
NewView Capital is a venture growth firm investing in high-potential enterprise technology, AI, and fintech companies. With more than $3B under management, NewView pairs a venture pedigree with flexible capital and operational impact. The firm’s portfolio includes category-defining companies such as Apollo, Databricks, Halter, Hinge Health, Huntress, Fin (fka Intercom), Legora, Mercury, Sigma, Stord, and Verkada.

For more information, visit nvc.vc.

About Carta
Carta is the connected platform and AI-native ecosystem for private capital. Built to replace fragmented tools with a single system of record, Carta brings together the software, services, and legal infrastructure that founders use to manage equity, fund managers use to run administration and reporting, and legal teams use to close transactions. Trusted by 55,000 companies and 1.8M+ equity holders in 160+ countries, and 10,000 funds and SPVs representing $250B in assets under management, Carta is transforming how private capital operates. Recognized by Fortune, Forbes, Fast Company, Inc. and Great Places to Work.

For more information, visit carta.com.

Media Contacts

NewView Capital
Prosek Partners: Pro-NewView@prosek.com 

Carta
Madeline Perry: madeline.perry@carta.com 

Important Information
This press release is for informational purposes only and does not constitute an offer, solicitation, or recommendation regarding any security, investment product, or investment advisory service.

Information is presented as of the publication date and may be based on information provided by NewView, Carta, or third-party sources that have not necessarily been independently verified. Statements regarding market trends, transaction activity, potential benefits, or future events are subject to risks and uncertainties, and actual outcomes may differ materially.

NewView and Carta have existing commercial relationships, including the collaboration described in this press release, and may receive related economic benefits, which may create an incentive to make favorable statements regarding each other or the collaboration. Neither party provided cash or non-cash compensation in connection with the quoted statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/newview-capital-and-carta-announce-strategic-collaboration-to-support-company-sponsored-tender-offers-302885312.html

SOURCE NewView Capital

Continue Reading

Technology

HIT COMEDY SERIES ‘OUT LOUD AND LAUGHING’ ANNOUNCES SEASON 4 LINEUP FEATURING CHRIS SALVATORE, PAUL WAGNER, EQUALPRIDE LEADERSHIP & MORE.

Published

on

By

New Season Premieres September 14 Across Out Magazine’s YouTube Network, Podcast Platforms, and OutLoudAndLaughing.com

NEW YORK, Sept. 22, 2026 /PRNewswire/ — Hit comedy interview series Out Loud and Laughing today announced its highly anticipated fourth season, partnering with leading LGBTQ+ media powerhouse equalpride (parent company of Out and The Advocate) for a major cross-platform distribution expansion. Premiering September 14, 2026, Season 4 will roll out across all major podcast platforms, the official website OutLoudAndLaughing.com, social channels, and Out Magazine’s newly revamped YouTube network.

Hosted by creators Bryan Ruiz and Jon Ruiz, Season 4 expands the show’s signature mix of bold comedy, unfiltered culture conversations, and candid interviews. The upcoming season features a dynamic slate of filmed talent alongside upcoming guest appearances, including:

Daniel Reynolds, Editor-in-Chief of Out MagazineRicky Cornish, Entertainment Editor at equalprideClaybourne Elder, Actor/SingerJake Graf, Actor/ScreenwriterJudy Gold, Comedian/ActorPaul Wagner, Actor/Adult StarChris Salvatore, Actor/SingerMaria Sjödin, ActivistDan Jinks, Film Producer (American Beauty, Milk, Big Fish)

NOW BOOKING: SEASON 4 TALENT CALLOUT 
As Out Loud and Laughing expands its footprint this season, the show is actively booking guests across the entire LGBTQIA+ spectrum. The platform is seeking compelling voices from entertainment, medicine, science, business, advocacy, and everyday culture makers doing groundbreaking work. Representatives and publicists looking to pitch talent for Season 4 appearances should contact [Insert Contact Email].

“We are thrilled to welcome Out Loud and Laughing into the Out family as we expand our digital video footprint,” said Mark Berryhill, CEO of equalpride. “As we relaunch Out Magazine’s YouTube platform, bringing Out Loud and Laughing on board perfectly aligns with our mission to elevate LGBTQ+ voices, foster joy, and deliver world-class entertainment alongside our trusted journalism and advocacy.”

With Out’s YouTube relaunch, audiences gain centralized access to premium video content from equalpride’s iconic portfolio—including Out, The Advocate, Out100, and Plus.

Season 4 of Out Loud and Laughing premieres September 14. Viewers can stream directly at youtube.com/outmagazine or listen wherever podcasts are available.

About equalpride
equalpride is the leading LGBTQ+-owned media company in the United States, delivering content across print, digital, streaming, and live events. Its portfolio includes iconic brands such as Out, The Advocate, Out100, Plus, and PRIDE.com, dedicated to inspiring, entertaining, and empowering the LGBTQ+ community worldwide.

About Out Loud and Laughing
Created and hosted by New York-based duo Bryan Ruiz and Jon Ruiz, Out Loud and Laughing is a celebrated comedy platform and interview show highlighting the funniest, boldest, and most vibrant voices in the LGBTQ+ community and beyond.

Media Contact & Booking Pitch Submissions: BryanAndJon@outloudandlaughing.com

Media Kit

PRESS CONTACT: Bryan Ruiz and Jon Ruiz | bryanandjon@outloudandlaughing.com | +1 917-981-7742

View original content to download multimedia:https://www.prnewswire.com/news-releases/hit-comedy-series-out-loud-and-laughing-announces-season-4-lineup-featuring-chris-salvatore-paul-wagner-equalpride-leadership–more-302885187.html

SOURCE Out Loud and Laughing

Continue Reading

Technology

QC Healthcare Announces Strategic Collaboration with Sanguina to Deploy AI-Powered Blood Health Technologies Across Nationwide Healthcare Platforms

Published

on

By

Collaboration will integrate Sanguina‘s AI-enabled patented fingernail analysis technology into My Pediatric Doctor and My Adult Doctor, with future applications through My VA Doctor and My Oncology Doctor and across maternal health, veterans’ health, oncology, hospital systems, clinical trials, and global healthcare initiatives.

CHARLOTTE, N.C. and ATLANTA, Sept. 22, 2026 /PRNewswire/ — QC Healthcare, a national healthcare innovation company focused on transforming patient access through technology, artificial intelligence, and connected care solutions, today announced a strategic collaboration with Sanguina, an AI-powered digital health company specializing in non-invasive fingernail analysis to derive blood health insights.

Through this collaboration, QC Healthcare will integrate Sanguina‘s innovative AI-driven screening capabilities for anemia, circulation, and other blood-health risk profiles across its growing healthcare ecosystem. The initial deployment will focus on My Pediatric Doctor, a nationwide 24/7 pediatric urgent care and primary care telehealth platform, and My Adult Doctor, a national 24/7 adult urgent care and primary care platform, with future applications planned for My VA Doctor and My Oncology Doctor.

The collaboration represents a significant advancement in the shared mission of QC Healthcare and Sanguina to deliver proactive, accessible, technology-enabled healthcare by bringing advanced screening tools directly into virtual care pathways. By leveraging artificial intelligence, digital biomarkers, and accessible patient-centered technology, QC Healthcare and Sanguina aim to improve early identification of issues in blood health, enhance remote clinical decision-making, and support more personalized healthcare delivery.

Addressing Global Healthcare Challenges Through Accessible Detection and Tracking

Anemia remains one of the most common blood-related conditions worldwide, affecting an estimated 1.9 billion people. Children, adults, pregnant and postpartum women, older adults, individuals with chronic diseases, cancer patients, and frequent blood donors are among the populations that may face elevated anemia risk and associated complications.

Most people learn their hemoglobin is low only when a lab draw happens to catch it. Between appointments, both patients and their care teams have no visibility at all. Sanguina‘s technology was built to close that gap, enabling frequent or on demand and personalized anemia screenings.

Additionally, Sanguina‘s circulation technology turns a fingernail video into a second measure of blood health. The Circulation Score quantifies the time and speed at which blood returns to the fingertips after they are briefly pressed and released, digitizing a bedside assessment clinicians have long used when evaluating peripheral perfusion. In the home setting, objective circulation trends may provide useful context for telehealth evaluations and may help clinicians determine whether follow-up assessment is appropriate for patients with symptoms or conditions associated with impaired circulation, dehydration, vascular disease, diabetes, cardiovascular concerns, recovery after illness or surgery, and other acute or chronic health needs. The score is intended to support screening, monitoring, and clinical decision-making; it is not, by itself, a diagnosis or a replacement for laboratory testing, physical examination, or emergency evaluation when indicated.

Integration into QC Healthcare‘s platforms puts it into use at national scale. By incorporating AI-enabled screening capabilities into digital healthcare workflows, QC Healthcare and Sanguina anticipate that patients can be identified earlier, evaluated more efficiently, and connected with appropriate clinical pathways before conditions become more serious.

“This collaboration represents the future direction of healthcare – moving from reactive treatment toward earlier identification, informed follow-up, and prevention,” said Eric Doherty, CEO of QC Healthcare. “By combining QC Healthcare‘s nationwide virtual care ecosystem with Sanguina‘s innovative AI technology, we can help bring meaningful blood-health information into the home and connect it to licensed clinical care. That opportunity extends across the families served by My Pediatric Doctor and My Adult Doctor today, as well as pregnant and postpartum women, veterans, and people navigating cancer who may benefit from the future My VA Doctor and My Oncology Doctor platforms.”

“Telehealth medicine enables accessible care,” said Erika Tyburski, CEO and Co-Founder of Sanguina. “Our fingernail analysis technologies push the accessible model further by equipping telehealth with on-demand tools that can be used at home to help fill missing data points between clinical interactions. Working with QC Healthcare creates an opportunity to connect anemia and circulation insights with care pathways serving children, adults, pregnant and postpartum women, veterans, and oncology patients at national scale.”

The initial focus of the collaboration will include integrating anemia and circulation screening into My Pediatric Doctor and My Adult Doctor, followed by evaluation of future applications across QC Healthcare‘s expanding platform portfolio.

Pediatric and Adult Virtual Care

Across My Pediatric Doctor, a nationwide 24/7 pediatric urgent care and primary care telehealth platform, anemia is a routine concern in childhood development, nutrition, and chronic disease management – and one that ordinarily requires a lab visit to investigate. My Adult Doctor, QC Healthcare‘s national 24/7 adult platform, serves patients managing fatigue and unexplained symptoms, adults with chronic conditions requiring ongoing monitoring, women during pregnancy and after childbirth, and patients participating in preventive health evaluations. In both settings, a between-visit blood-health history can provide clinicians with added context when deciding whether laboratory testing, an in-person examination, referral, or other follow-up is warranted.

Maternal Health, Oncology, and Veterans’ Care

Pregnancy and the postpartum period are major areas of potential impact. Iron needs rise during pregnancy, and blood loss during delivery can contribute to postpartum anemia. When clinically appropriate, convenient at-home screening and trend information could help women and their care teams recognize changes sooner, support follow-up after delivery, and connect patients with confirmatory testing and treatment. QC Healthcare‘s relationship with families through My Adult Doctor and My Pediatric Doctor creates a natural bridge between maternal care and pediatric care during a period when mothers may otherwise place their own health needs behind those of a newborn. Cancer patients may experience anemia related to disease, treatment, blood loss, or nutrition, and QC Healthcare‘s planned My Oncology Doctor platform is intended to support monitoring and care coordination between oncology visits. My VA Doctor, also in development, will extend appropriate blood-health and circulation applications to veterans, including those managing chronic disease, mobility limitations, recovery needs, or barriers to in-person care.

Building a Digital Blood Health Network

The collaboration draws on capabilities both companies are assembling into a single connected care network — artificial intelligence, telehealth, digital diagnostics, remote monitoring, data analytics, clinical research, and preventive care operating as one pathway rather than seven separate services. That integration is also what makes the model portable. The infrastructure gap that keeps a rural patient from a routine blood panel is the same gap facing health organizations across much of the world, and both companies intend to pursue international deployments, working with healthcare organizations abroad to adapt the model for populations where laboratory access is thinnest, and the need is greatest.

Health Systems, Payers, and Employers

Beyond direct-to-patient virtual care, the two companies will pursue potential deployments with hospitals, health systems, employers, payers, maternal-health programs, veterans’ organizations, oncology programs, and research partners. Potential applications include remote monitoring, population health and chronic disease management, prenatal and postpartum follow-up, discharge follow-up, preventive health campaigns, and clinically guided pathways for additional evaluation.

Clinical Research and Evidence Generation

The collaboration will also support clinical validation studies, real-world evidence generation, and clinical trial recruitment and coordination, drawing on Sanguina‘s published clinical data and QC Healthcare‘s nationwide patient reach. Any expansion into new clinical uses will follow appropriate clinical validation and regulatory review.

Working with QC Healthcare and Sanguina

Health systems, payers, employers, maternal-health organizations, veterans’ organizations, oncology programs, blood collection organizations, and research partners interested in exploring deployments can contact QC Healthcare through its platform websites or Sanguina at partnerships@sanguina.ai.

About QC Healthcare

QC Healthcare is a healthcare holding and innovation company focused on building and scaling connected healthcare businesses through artificial intelligence, digital health technologies, nationwide virtual care, strategic partnerships, clinical research, and data-driven solutions.

Through its growing ecosystem – including My Pediatric Doctor and My Adult Doctor, with My VA Doctor and My Oncology Doctor in development – QC Healthcare is creating a connected model of care designed to improve access, strengthen continuity, support better-informed clinical decisions, and accelerate responsible healthcare innovation. Learn more and follow QC Healthcare on LinkedIn.

About Sanguina

Sanguina is an AI-powered digital health company focused on improving awareness, screening, tracking, and management of blood health through accessible and innovative technology solutions. The company is led by CEO and Co-Founder Erika Tyburski.

The company’s technology platform represents a new approach to leveraging artificial intelligence and digital health tools to enable and support non-invasive health measurements on demand, in remote, point-of-care and home settings. Learn more at Sanguina.com and follow Sanguina on LinkedIn.

About My Pediatric Doctor

My Pediatric Doctor provides nationwide, 24/7 pediatric urgent and primary care telehealth, giving families convenient access to experienced U.S.-based clinicians across all 50 states, Puerto Rico, and Guam. The platform accepts insurance and also supports direct-pay access. Learn more at MyPediatricDoctor.com or follow My Pediatric Doctor on LinkedIn.

About My Adult Doctor

My Adult Doctor provides nationwide, 24/7 adult urgent and primary care telehealth across all 50 states, Puerto Rico, and Guam. Its connected care model is designed to support acute needs, preventive care, chronic disease management, medication management, laboratory ordering, referrals, care coordination, and wellness services. Learn more at MyAdultDoctor.com or follow My Adult Doctor on LinkedIn.

Media Contact

QC Healthcare and My Adult Doctor: contact@MyAdultDoctor.com | My Pediatric Doctor: contact@MyPediatricDoctor.com | Sanguina: partnerships@sanguina.ai

View original content to download multimedia:https://www.prnewswire.com/news-releases/qc-healthcare-announces-strategic-collaboration-with-sanguina-to-deploy-ai-powered-blood-health-technologies-across-nationwide-healthcare-platforms-302886131.html

SOURCE QC Healthcare

Continue Reading

Technology

LexisNexis Risk Solutions Study Finds SNAP Fraud Costs Have Reached a Five-Year High

Published

on

By

Agencies now incur an average of $4.29 in total costs for every $1 lost to fraud as payment accuracy, data quality and eligibility challenges continue to mount.

WASHINGTON, Sept. 22, 2026 /PRNewswire/ — LexisNexis® Risk Solutions today released its fifth annual True Cost of Fraud™ Study for SNAP Agencies and Integrated Eligibility Systems (IES), finding that state and county Supplemental Nutrition Assistance Program (SNAP) agencies now incur an average of $4.29 in total costs for every $1 in benefits lost to fraud.  This average cost is the highest level reported in the study’s five-year history. The research comes as agencies face growing pressure to improve payment accuracy, protect taxpayer resources, and deliver timely benefits while implementing new federal requirements and managing increasingly complex eligibility decisions.

A nationwide survey of 150 state and county SNAP agency decision-makers found that agencies are navigating an increasingly challenging operating environment shaped by payment accuracy requirements, evolving eligibility policies, administrative resource constraints, increasingly sophisticated fraud schemes and growing expectations for faster benefit delivery.

The survey findings point to a broader challenge. Agencies are not only confronting fraud, but also balancing increasingly complex eligibility requirements, payment accuracy expectations, administrative demands, and program integrity responsibilities. States are preparing for policy changes associated with H.R. 1 that affect SNAP eligibility requirements and program administration while also working to improve payment accuracy, manage administrative resources, and ensure eligible families receive benefits on time.

Key Findings

SNAP fraud costs reached a five-year high. Agencies now incur an average of $4.29 in total costs for every $1 lost to fraud, reflecting the growing operational and financial burden of fraud on public benefit programs.Higher payment error rates carry higher costs. Agencies reporting stronger payment accuracy also reported lower fraud-related costs, highlighting the close connection between improper payments, administrative burden and program integrity.Eligibility information gaps are adding pressure to agency operations. Agencies continue to face challenges accessing the information needed to verify eligibility, support program integrity and make timely benefit decisions.Document-related threats are increasing complexity. Agencies reported growing challenges involving document authentication and manipulated documents, demonstrating the impact of increasingly sophisticated digital and AI-enabled fraud schemes.Cross-program fraud exposure continues to rise. As integrated eligibility systems expand, agencies are encountering increased fraud risk across multiple benefit programs and eligibility environments.Better data supports earlier fraud prevention. Agencies with stronger access to trusted data and fewer information gaps were significantly more successful at identifying and preventing fraud before benefits were issued.

“The real cost of fraud today extends far beyond stolen benefits,” said Haywood Talcove, Chief Executive Officer, Government, LexisNexis Risk Solutions. “Agencies are being asked to make faster, more accurate decisions, while managing increasingly sophisticated fraud schemes, rising payment integrity expectations and growing operational demands. Our study shows that success depends on more than technology alone. Agencies achieve stronger outcomes when modernization is paired with trusted identity, income and eligibility intelligence that helps caseworkers make informed decisions, reduce improper payments and protect critical benefits.”  

As policymakers and agency leaders navigate evolving federal requirements, the research reinforces that payment accuracy, administrative efficiency, program integrity and timely benefit delivery are interconnected. Strengthening access to authoritative identity, income and eligibility information can help agencies make better decisions earlier, reduce administrative burden, protect taxpayer resources and preserve access for eligible families.

About the Study

The fifth annual LexisNexis Risk Solutions True Cost of Fraud™ Study for SNAP Agencies and Integrated Eligibility Systems surveyed 150 senior state and county SNAP agency decision-makers and administrators in June 2026. The study examined fraud trends, payment error rates, integrated eligibility systems, modernization, data challenges, program integrity and expected impacts of policy changes associated with H.R. 1. LexisNexis Risk Solutions was not identified as the sponsor of the research.

About LexisNexis Risk Solutions

LexisNexis® Risk Solutions harnesses the power of data and advanced analytics to provide insights that help businesses and governmental entities reduce risk and improve decisions to benefit people around the globe. We provide data and technology solutions for a wide range of industries including insurance, financial services, healthcare, and government. Headquartered in metro Atlanta, Georgia, we have offices throughout the world and are part of RELX (LSE: REL/NYSE: RELX), a global provider of information and analytics for professional and business customers. For more information, please visit www.risk.lexisnexis.com and www.relx.com.

Media Contact:
Paul Eckloff
LexisNexis Risk Solutions
Mobile: +1.202.941.6986
Paul.Eckloff@lnssi.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/lexisnexis-risk-solutions-study-finds-snap-fraud-costs-have-reached-a-five-year-high-302884856.html

SOURCE LexisNexis Risk Solutions

Continue Reading

Trending